Specifically, siRNA-mediated interventions [48–50] designed to inhibit Wnt/β-catenin signaling, NIK/non-canonical NF-κB, and/or NRF2 expression, individually or in combination, could potentially prevent the transition from NASH to HCC, and improve the efficacy of existing HCC treatments. This evidence concerns the gene MAP3K14 and metabolic dysfunction-associated steatohepatitis.